Share price’s recent ride doesn’t track with analysts’ regard for C&D’s results and outlook.

Health, personal and household care product marketer says raising its annual guidance model from 3% organic growth to 4% driven by expectations for international sales growth, a return to volume-driven sales growth and outlook for Hero and TheraBreath brands.

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

Higher costs and interest rates due to inflation as well as higher credit card debt point toward consumers spending less in areas including health, personal and household care products. C&D is “well-positioned for this trade down” with 40% of its portfolio in value products, says CEO Matthew Farrell.